The latest announcement is out from Chemomab Therapeutics ( (CMMB) ).
On November 15, 2024, Chemomab Therapeutics Ltd. filed a prospectus supplement under its Sales Agreement with Roth Capital Partners, LLC, initially dated October 16, 2023. This filing updates the amount of American Depositary Shares (ADSs) the company can sell, allowing for an aggregate offering price of up to $8,626,564. This move is part of Chemomab’s strategy to enhance its financial flexibility and support its ongoing research and development activities. The issuance of these shares is expected to be valid and fully compliant with Israeli law, as confirmed by the opinion of Meitar | Law Offices.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is a biotechnology company based in Tel Aviv, Israel, focused on developing therapies for fibrotic and inflammatory diseases. The company is involved in the research and development of monoclonal antibodies targeting key pathways in these medical conditions.
YTD Price Performance: -36.62%
Average Trading Volume: 363,242
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $27.15M
For a thorough assessment of CMMB stock, go to TipRanks’ Stock Analysis page.